Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XEYCE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AXL02-MMAE
|
|||||
| Synonyms |
AXL02-MMAE
Click to Show/Hide
|
|||||
| Organization |
Fudan University School of Pharmacy.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
AXL02
|
Antibody Info | ||||
| Antigen Name |
Tyrosine-protein kinase receptor UFO (AXL)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
DBCO-Azide Click Chemistry Conjugation
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Lung large cell carcinoma | LCLC-103H cells | CVCL_1375 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | Hs578T cells | CVCL_0332 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Lung adenocarcinoma | PC9 cells | CVCL_B260 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Lung squamous cell carcinoma | Calu-1 cells | CVCL_0608 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Low AXL expression (AXL+) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
References